157 related articles for article (PubMed ID: 32112545)
1. Molecular biomarkers in the diagnostic of patients with colorectal cancer.
Fabišíková K; Behulová RL; Repiska V
Neuro Endocrinol Lett; 2019 Dec; 40(5):215-221. PubMed ID: 32112545
[TBL] [Abstract][Full Text] [Related]
2. Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study.
Sui J; Wu X; Wang C; Wang G; Li C; Zhao J; Zhang Y; Xiang J; Xu Y; Nian W; Cao F; Yu G; Lou Z; Hao L; Liu L; Li B; Zhang Z; Cai S; Liu H; Lan P; Zhang W
Clin Epigenetics; 2021 Feb; 13(1):26. PubMed ID: 33536049
[TBL] [Abstract][Full Text] [Related]
3. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
Vymetalkova V; Cervena K; Bartu L; Vodicka P
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199
[TBL] [Abstract][Full Text] [Related]
4. Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction.
Nassar FJ; Msheik ZS; Nasr RR; Temraz SN
Clin Epigenetics; 2021 May; 13(1):111. PubMed ID: 34001239
[TBL] [Abstract][Full Text] [Related]
5. Congenital genetic instability in colorectal carcinomas.
Svendsen LB
Dan Med Bull; 1993 Nov; 40(5):546-56. PubMed ID: 8299399
[TBL] [Abstract][Full Text] [Related]
6. Role of miRNA-210, miRNA-21 and miRNA-126 as diagnostic biomarkers in colorectal carcinoma: impact of HIF-1α-VEGF signaling pathway.
Sabry D; El-Deek SEM; Maher M; El-Baz MAH; El-Bader HM; Amer E; Hassan EA; Fathy W; El-Deek HEM
Mol Cell Biochem; 2019 Apr; 454(1-2):177-189. PubMed ID: 30357530
[TBL] [Abstract][Full Text] [Related]
7. Current and future molecular diagnostics in colorectal cancer and colorectal adenoma.
Tsang AH; Cheng KH; Wong AS; Ng SS; Ma BB; Chan CM; Tsui NB; Chan LW; Yung BY; Wong SC
World J Gastroenterol; 2014 Apr; 20(14):3847-57. PubMed ID: 24744577
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer.
Luo H; Zhao Q; Wei W; Zheng L; Yi S; Li G; Wang W; Sheng H; Pu H; Mo H; Zuo Z; Liu Z; Li C; Xie C; Zeng Z; Li W; Hao X; Liu Y; Cao S; Liu W; Gibson S; Zhang K; Xu G; Xu RH
Sci Transl Med; 2020 Jan; 12(524):. PubMed ID: 31894106
[TBL] [Abstract][Full Text] [Related]
9. 5-Hydroxymethylcytosine signature in circulating cell-free DNA as a potential diagnostic factor for early-stage colorectal cancer and precancerous adenoma.
Xiao Z; Wu W; Wu C; Li M; Sun F; Zheng L; Liu G; Li X; Yun Z; Tang J; Yu Y; Luo S; Sun W; Feng X; Cheng Q; Tao X; Wu S; Tao J
Mol Oncol; 2021 Jan; 15(1):138-150. PubMed ID: 33107199
[TBL] [Abstract][Full Text] [Related]
10. Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer.
Zhang J; Raju GS; Chang DW; Lin SH; Chen Z; Wu X
Cancer; 2018 Feb; 124(4):785-796. PubMed ID: 29112225
[TBL] [Abstract][Full Text] [Related]
11. Colorectal Adenomas-Genetics and Searching for New Molecular Screening Biomarkers.
Siskova A; Cervena K; Kral J; Hucl T; Vodicka P; Vymetalkova V
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32380676
[TBL] [Abstract][Full Text] [Related]
12. Consensus molecular subtype classification of colorectal adenomas.
Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
[TBL] [Abstract][Full Text] [Related]
13. Molecular biology of colorectal cancer.
Gryfe R; Swallow C; Bapat B; Redston M; Gallinger S; Couture J
Curr Probl Cancer; 1997; 21(5):233-300. PubMed ID: 9438104
[TBL] [Abstract][Full Text] [Related]
14. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
[TBL] [Abstract][Full Text] [Related]
15. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.
Farshidfar F; Weljie AM; Kopciuk KA; Hilsden R; McGregor SE; Buie WD; MacLean A; Vogel HJ; Bathe OF
Br J Cancer; 2016 Sep; 115(7):848-57. PubMed ID: 27560555
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of colorectal neoplasia among family members of patients with colorectal cancer: a population-based study in Utah.
Samadder NJ; Curtin K; Tuohy TM; Rowe KG; Mineau GP; Smith KR; Pimentel R; Wong J; Boucher K; Burt RW
Gastroenterology; 2014 Oct; 147(4):814-821.e5; quiz e15-6. PubMed ID: 25042087
[TBL] [Abstract][Full Text] [Related]
17. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
18. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
[TBL] [Abstract][Full Text] [Related]
19. New trends in molecular and cellular biomarker discovery for colorectal cancer.
Aghagolzadeh P; Radpour R
World J Gastroenterol; 2016 Jul; 22(25):5678-93. PubMed ID: 27433083
[TBL] [Abstract][Full Text] [Related]
20. Quantitative proteomic analysis exploring progression of colorectal cancer: Modulation of the serpin family.
Peltier J; Roperch JP; Audebert S; Borg JP; Camoin L
J Proteomics; 2016 Oct; 148():139-48. PubMed ID: 27492143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]